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OBJECTIVES We sought to evaluate the long-term effects of alternative right ventricular pacing sites on
myocardial function and perfusion.
BACKGROUND Previous studies have demonstrated that asynchronous ventricular activation due to right
ventricular apical (RVA) pacing alters regional myocardial perfusion and functions.
METHODS We randomized 24 patients with complete atrioventricular block to undergo permanent
ventricular stimulation either at the RVA (n 12) or right ventricular outflow (RVOT) (n
12). All patients underwent dipyridamole thallium myocardial scintigraphy and radionuclide
ventriculography at 6 and 18 months after pacemaker implantation.
RESULTS After pacing, the mean QRS duration was significantly longer during RVA pacing than
during RVOT pacing (151  6 vs. 134  4 ms, p  0.03). At six months, the incidence of
myocardial perfusion defects (50% vs. 25%) and regional wall motion abnormalities (42% vs.
25%) and the left ventricular ejection fraction (LVEF) (55  3% vs. 55  1%) were similar
during RVA pacing and RVOT pacing (p  0.05). However, at 18 months, the incidence of
myocardial perfusion defects (83% vs. 33%) and regional wall motion abnormalities (75% vs.
33%) were higher and LVEF (47 3 vs. 56 1%) was lower during RVA pacing than during
RVOT pacing (all p  0.05). Patients with RVA pacing had a significant increase in the
incidence of myocardial perfusion defects (p  0.05) and a decrease in LVEF (p  0.01)
between 6 and 18 months, but patients with RVOT pacing did not (p  0.05).
CONCLUSIONS This study demonstrates that preserved synchronous ventricular activation with RVOT
pacing prevents the long-term deleterious effects of RVA pacing on myocardial perfusion and
function in patients implanted with a permanent pacemaker. (J Am Coll Cardiol 2002;40:
1451–8) © 2002 by the American College of Cardiology Foundation
Asynchronous ventricular activation during ventricular pac-
ing is associated with abnormal regional myocardial blood
flow and metabolism and reduces systolic and diastolic left
ventricular (LV) function (1–5). Furthermore, these func-
tional abnormalities of ventricular pacing appear to have
potential deleterious effects over time. Experimental studies
have demonstrated that long-term right ventricular apical
(RVA) pacing induces abnormal histologic changes with
myofibrillar disarray, as well as asymmetrical LV hypertro-
phy and thinning (6–9). In a previous clinical study, we have
shown that long-term RVA pacing leads to regional myo-
cardial perfusion defects and wall motion abnormalities,
which become more pronounced as the duration of pacing
increases, and subsequently impairs LV function (10). In
animal studies, pacing at the right ventricular outflow tract
(RVOT) to decrease the asynchrony of activation amelio-
rated the reduction in LV function and prevented the
development of myofibrillar disarray (11,12). However,
clinical studies of RVOT pacing have yielded inconsistent
results (13–16), and the long-term effects of RVOT pacing
on myocardial perfusion and function are unclear.
The purpose of this prospective, randomized study was to
evaluate the long-term effects of RVA pacing and RVOT
pacing on myocardial perfusion and function in patients
implanted with a permanent dual-chamber pacemaker.
METHODS
Patients. The study included 30 consecutive patients (14
men and 16 women; mean [SEM] age 78  2 years
[range 59 to 88]) with complete atrioventricular (AV) block
admitted for pacemaker implantation. Patients with a his-
tory of coronary artery disease, significant valvular disease,
congestive heart failure, hypertension or LV hypertrophy, or
a left ventricular ejection fraction (LVEF) 50% on the
baseline screening echocardiogram were excluded from the
study. Their mean LVEF was 59  3% by echocardiogra-
phy.
Study protocol. All patients underwent implantation of a
dual-chamber pacemaker using one passive fixation atrial
lead and one active fixation ventricular lead (commercially
available bipolar leads could be used). Patients were ran-
domized, using a randomization table at the time of
implantation, to receive a ventricular lead at either at the
RVA or RVOT position. Atrial leads were positioned to the
right atrial lateral wall. Surface limb leads (I, II, III, aVR,
aVL, and aVF) of the electrocardiogram (ECG) were
recorded with a paper speed of 100 mm/s during the
procedure, and the QRS duration was measured from the
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earliest to latest deflection of the QRS complex. After
pacemaker implantation, optimization of the AV delay was
performed by using pulsed Doppler echocardiography of the
transmitral blood flow, as previously described (17). All
patients underwent 24-h Holter monitoring, dipyridamole
thallium-201 (Tl-201) myocardial scintigraphy, and radio-
nuclide ventriculography at 6 and 18 months after pace-
maker implantation. Patients with Tl-201 perfusion defects
were referred for a coronary angiographic study. Patients
with significant coronary artery stenosis (50%) were ex-
cluded from the study. The study protocol was approved by
the local Ethics Committee, and all patients gave written,
informed consent.
Lead implantation. The ventricular pacing lead was in-
serted into the RV through a left cephalic vein cutdown or
subclavian puncture. Under fluoroscopic guidance, the ven-
tricular lead was positioned in the RVA in those patients
randomized to RVA pacing. In patients who underwent
RVOT pacing, the ventricular lead was advanced through
the tricuspid valve and then withdrawn far enough to
position the tip against the interventricular septum, as
verified by multiple fluoroscopic views (Fig. 1). Then,
mapping of the interventricular septum was performed by
using the screw-in tip of the lead with a custom-shaped
stylet. The optimal RVOT lead position was confirmed by
fluoroscopy and the limb leads of the ECG demonstrating
an inferior axis in the frontal axis and the narrowest QRS
complex available (Fig. 2). An external pacing system
analyzer was used to measure the ventricular capture thresh-
old at a pulse duration of 0.5 ms, R-wave amplitude, and
lead impedance. All the ventricular pacing leads were
positioned at a stable position to obtain a satisfactory pacing
threshold value (mean 1.1  0.2 V [range 0.5 to 1.5]) at a
pulse width of 0.5 ms and R-wave sensing value (mean 12.3
 0.1 mV [range 6.5 to 20.5]).
Holter recording. Bipolar ECG leads were fixed to the
chest at V1 and V6; all ECGs were recorded for 24 h with
an Oxford Medilog recorder (Oxford Medical Instruments,
Oxford, U.K.). The ECG complexes of the first minute of
each hour were printed and reviewed at a paper speed of 25
mm/s. Complete ventricular capture was defined by the
presence of a pacing spike followed by QRS complexes with
a QRS width equal to that during VVI pacing without
fusion. The percentage of QRS complexes with ventricular
capture during each observation minute was averaged to
obtain the 24-h percentage of complete capture.
Dipyridamole Tl-201 myocardial scintigraphy. All pa-
tients were instructed to fast for 6 h and to avoid medica-
tions containing methylxanthine and beverages containing
caffeine for 24 h before the test. Dipyridamole (0.56 mg/kg
body weight) was infused for 4 min, and 3 min later, 2 mCi
of Tl-201 chloride was injected intravenously. Thallium-
201 single-photon emission computed tomographic imag-
ing was performed at 15 min and at 4 h after the injection.
An additional 1 mCi of Tl-201 was injected before the rest
study at 4 h. If a fixed defect was detected in the 4-h image,
imaging was also performed at 24 h. Sagittal, short-axis, and
long-axis tomograms were constructed from the raw scin-
tigraphic data. These constructed stress and rest images
were then analyzed qualitatively using the 20-segment/5-
point scoring system (18). The 20-segment scoring system
is based on three short-axis slices (apical, mid, and basal) to
represent the entire LV, with the apex represented by one
segment visualized by a mid-vertical long-axis image. Per-
fusion was scored qualitatively by two experienced observers,
in blinded manner, using a 5-point scale: 0  normal; 1 
slight reduction of uptake (equivocal); 2  moderate reduc-
tion of uptake; 3  severe reduction of uptake; and 4 




LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
RV  right ventricle/ventricular
RVA  right ventricular apex
RVOT  right ventricular outflow tract
Tl-201  thallium-201
Figure 1. Fluoroscopic images of the (left) posteroanterior (PA) and (right) left anterior oblique (LAO) projection, showing the position of the active
ventricular pacing lead at the right ventricular outflow tract (arrow).
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Radionuclide ventriculography. Multiple-gated equilib-
rium blood pool imaging was performed at rest to determine
global and regional LVEF and to assess regional wall
motion. Patients’ red blood cells were labeled with 20 to 30
mCi of technetium-99m by using the modified in vivo
technique (19). Data were acquired in an ECG-
synchronized frame mode (32 frames/cycle with 150,000 to
200,000 counts/frames) in a 64  64 computer matrix.
Global LVEF was computed from the left anterior oblique
image by means of a semi-automated, operator-assisted
method to define the border of the LV and background and
by using validated and standardized software (20). The
LVEF was determined from the fitted curve in the usual
manner: (end-diastolic counts  end-systolic counts)/end-
diastolic counts. The reproducibility of LVEF measure-
ments using this software is excellent (21). Left ventricular
diastolic function was assessed by measuring the peak
ventricular filling rate derived from the gated equilibrium,
high-resolution LV time–activity curves (20,22).
Regional LVEF was calculated by segmenting the left
anterior oblique view of the LV into five regions: septal,
anterior, apical, inferior, and lateral. The stroke counts over
end-diastolic counts in each segment were used to deter-
mine regional LVEF (23). Furthermore, serial frames of the
image were displayed for cineangiographic wall motion
assessment. Regional wall motion was scored in each of the
five segments as normal, hypokinetic, akinetic, or dyskinetic
by two experienced observers in a blinded manner (10).
Statistical analysis. Continuous data are expressed as the
mean value  SEM. Comparisons between the two groups
were performed by the Mann-Whitney U test for continu-
ous variables and by the Fisher exact test for dichotomous
variables. The paired Student t test was used to compare the
change in variables in each group between the 6- and
18-month evaluations. Multiple comparisons of the regional
ejection fraction between the 6- and 18-month evaluations
during RVA and RVOT pacing were performed using
two-way repeated measures analysis of variance, followed by
the Bonferroni t test for individual comparisons. A p value
 0.05 was considered as statistically significant.
RESULTS
Patient characteristics. At baseline, 16 patients were ran-
domized to receive RVA pacing and 14 patients to RVOT
pacing. There were no significant differences in age, gender
distribution, baseline LVEF by echocardiography, ventricular
pacing variables, and percentage of ventricular pacing between
Figure 2. Twelve-lead electrocardiogram of a patient who underwent right ventricular outflow tract pacing, showing a QRS duration of 135 ms with a left
bundle branch block pattern and inferior axis.
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the two groups (all p  0.05). No complications or lead
dislodgment was observed during the study. All patients were
in sinus rhythm and maintained AV pacing throughout the
study period. Of the 30 patients initially included in the study,
20 (67%) had perfusion defects on the dipyridamole Tl-201
myocardial scintigraphic image. Six of them had significant
coronary artery disease, as detected by coronary angiography,
and were excluded from the final analysis. The mean age of the
remaining 24 patients (11 men and 13 women) was 75  5
years. Twelve patients were randomized to RVA pacing and
the remaining 12 patients to RVOT pacing. Their clinical
characteristics are shown in Table 1. There was no significant
difference in age, gender distribution, intrinsic rhythm, baseline
LVEF, or prevalence of regional wall motion abnormalities by
echocardiography, ventricular pacing variables, and percentage
of ventricular pacing between the two groups. However, the
mean QRS duration was significantly longer during RVA
pacing than during RVOT pacing (Table 1).
At pre-discharge echocardiography, there was no signif-
icant difference in LVEF, prevalence of regional wall
motion abnormalities, cardiac output, as measured by
Doppler echocardiography, optimal AV interval, or trans-
mitral A- and E-wave ratio between the two group (Table
1). Furthermore, there was also no significant difference in
LVEF, as measured by echocardiography, between the base-
line and pre-discharge follow-up in the two groups (p 0.05).
Dipyridamole Tl-201 myocardial scintigraphy. All pa-
tients were paced continuously throughout the study. There
were no significant differences between patients with RVA
and RVOT pacing in the maximal heart rate during
pharmacologic stress at 6 months (87  3 vs. 89  2
beats/min, p  0.34) and 18 months (90  2 vs. 86  3
beats/min, p  0.18).
At six months, six patients (50%) with RVA pacing and
three patients (25%) with RVOT pacing showed perfusion
defects on the dipyridamole myocardial scintigraphic image
(p  0.40). There were also no significant differences in the
summed rest score (5.3  1.6 vs. 2.2  0.6 (p  0.08) or
summed stress score (8.1  1.8 vs. 4.8  1.0, p  0.12)
between the two groups (Fig. 3). Perfusion defects were
located in the inferior (83%, n 5) and apical (67%, n 4)
wall during RVA pacing and in the septum (100%, n  3)
during RVOT pacing.
At 18 months, 10 patients (83%) with RVA pacing and
4 patients (33%) with RVOT pacing showed perfusion
defects on the dipyridamole myocardial scintigraphic image




(n  12) p Value
Age (yrs) 72.3  8 77  5 0.12
Male 4 (33%) 6 (50%) 0.68
Intrinsic rhythm
LBBB 3 (25%) 4 (33%) 1.0
RBBB 4 (33%) 4 (33%) 1.0
IVCD 2 (17%) 1 (9%) 1.0
Narrow QRS 1 (17%) 2 (17%) 1.0
Not available 2 (17%) 1 (9%) 1.0
Other medical illnesses
Diabetes 2 (17%) 2 (17%) 1.0
Hyperlipidemia 3 (33%) 2 (17%) 1.0
Medications
Oral hypoglycemic agents 1 (9%) 2 (17%) 1.0
Lipid-lowering agents 2 (17%) 1 (9%) 1.0
Baseline echocardiography
LVEF 57  12% 59  14% 0.74
Regional wall motion abnormalities 3 (25%) 2 (17%) 1.0
Pre-discharge echocardiography
LVEF 56  10% 57  13% 0.36
Regional wall motion abnormalities, n (%) 4 (33%) 3 (25%) 1.0
Cardiac output (l/min) 3.6  0.4 3.8  0.5 0.45
E/A ratio 0.8  0.3 1.0  0.2 0.25
Optimal atrioventricular interval (ms) 140  37 146  36 0.49
Pacing variable at 6 months
Ventricular pacing threshold (V/0.5 ms) 1.2  0.5 1.4  0.7 0.53
R-wave amplitude (mV) 12.5  5.5 9.1  4.5 0.10
Impedance () 560  175 587  174 0.73
Percent ventricular pacing
6-month follow-up 96  11% 96  10% 0.28
18-month follow-up 95  16% 97  14% 0.36
QRS duration (ms) 151  21 134  15 0.034
Data are expressed as the mean value  SEM or number (%) of patients.
E/A  early transmitral flow velocity to atrial flow velocity; IVCD  intraventricular conduction delay; LBBB  left bundle
branch block; LVEF  left ventricular ejection fraction; RBBB  right bundle branch block; RVA  right ventricular apex;
RVOT  right ventricular outflow tract.
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(p  0.04). Pacing at the RVA was associated with a
significantly higher summed rest score (7.9  1.5 vs. 2.2 
0.5, p  0.01) and summed stress score (13.3  2.6 vs. 4.9
 1.1, p  0.01), compared with RVOT pacing (Fig. 3).
Perfusion defects were located in the inferior (90%, n  9),
apical (80%, n  8), septal (20%, n  2), and lateral (10%,
n  1) wall during RVA pacing and in the septal (100%, n 
4) and anterior (25%, n  1) wall during RVOT pacing.
In patients with RVA pacing, the incidence of perfusion
defects, the summed rest score, and the summed stress score
were significantly higher at 18 months than at 6 months,
suggesting worsening of myocardial perfusion over time (all
p  0.05). These variables were similar at 6 and 18 months
in patients with RVOT pacing (all p  0.05).
Radionuclide ventriculography. At six months, five pa-
tients (42%) with RVA pacing and three patients (25%)
with RVOT pacing showed regional wall motion abnormal-
ities on the radionuclide ventriculogram (p  0.20). During
RVA pacing, apical and septal regional LVEFs were signif-
icantly diminished compared with those in the anterior,
inferior, and lateral regions (p  0.05) (Table 2). During
RVOT pacing, the LVEF in the septal region was signifi-
cantly diminished compared with that in all the other
regions (p 0.05), and the LVEF in the inferior region was
higher than that in the anterior, lateral, and septal regions
(p  0.05) (Table 2). The LVEF in the apical and inferior
regions was significantly lower during RVA pacing than
during RVOT pacing (p  0.05) (Fig. 4). There was no
significant difference in the global LVEF, as measured by
pre-discharge echocardiography and radionuclide ventricu-
lography at six months, in patients with RVA pacing (56 
10% vs. 55 10%, p 0.76) and RVOT pacing (57 13%
vs. 55  45%, p  0.36). The global LVEF was similar
during RVA pacing and RVOT pacing (p  0.58); how-
ever, the peak ventricular filling rate was significantly lower
Figure 3. The summed rest (upper panel) and stress (lower panel) scores
for dipyridamole thallium-201 myocardial scintigraphy after 6 and 18
months of right ventricular apex (RVA) (solid bars) and right ventricular
outflow tract (RVOT) (open bars) pacing. The summed rest and stress
scores during RVA pacing at 18 months were significantly higher than
those during RVOT pacing at 18 months (p  0.05) and during RVA
pacing at 6 months (p  0.05).
Table 2. Regional and Global Left Ventricular Ejection Fraction (%)
Regions
Global Lateral Inferior Apical Septal Anterior
RVA
6 months 55  3 63  3†‡ 53  4†‡ 31  3 40  2 48  4†‡
18 months 47  3* 54  4*†‡ 53  4†‡ 30  4 37  3 42  5*
RVOT
6 months 55  1 69  2† 81  2† 77  2† 36  2 60  2†
18 months 56  1 71  2† 82  2† 76  2† 36  2 57  2†
*p  0.05 compared with RVA pacing at 6 months. †p  0.05 compared with the septal region. ‡p  0.05 compared with the
apical region. Data are expressed as the mean value  SEM.
Abbreviation as in Table 1.
Figure 4. Regional left ventricular ejection fraction (EF) at the lateral,
inferior, apical, septal, and anterior regions after 6 and 18 months of right
ventricular apex (RVA) and right ventricular outflow tract (RVOT) pacing.
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during RVA pacing than during RVOT pacing (1.66 
0.50 vs. 2.37  0.64/s, p  0.01) (Fig. 5).
At 18 months, nine patients (75%) with RVA pacing and
four patients (33%) with RVOT pacing showed regional
wall motion abnormalities on the radionuclide ventriculo-
gram (p  0.04). During RVA pacing, the LVEF in the
apical and septal regions was significantly diminished, com-
pared with that in the inferior and lateral regions (p 0.05)
(Table 2). During RVOT pacing, the LVEF in the septal
region was significantly diminished compared with that in
all the other regions (p  0.05), and the LVEF in the
inferior region was higher than that in the anterior, lateral,
and septal regions (p  0.05) (Table 2). The LVEF in the
apical and inferior regions was significantly lower during
RVA pacing than during RVOT pacing (p 0.05) (Fig. 4).
Both the global LVEF (56  1% vs. 47  3%, p  0.02)
and peak ventricular filling rate (1.66  0.16 vs. 2.49 
0.21/s, p  0.01) were significantly lower during RVA
pacing than during RVOT (Fig. 5).
In patients with RVA pacing, there was a significant
interval decrease in regional LVEF over the lateral and
anterior regions (p  0.05) (Fig. 4). As a result, global
LVEF during RVA pacing was reduced at 18 months versus
6 months (p  0.01). However, there were no interval
changes in regional and global LVEF in patients with
RVOT pacing (p  0.05) (Table 2). The peak ventricular
filling rate was similar at 6 and 18 months in both groups
(p  0.05).
DISCUSSION
Main findings. The results of this study demonstrate that
RVA pacing leads to a high incidence of regional myocar-
dial perfusion and wall motion abnormalities near the sites
of electrical stimulation, which increase with the duration of
pacing. These functional abnormalities during RVA pacing
are associated with impairment of LV diastolic function and
progressive deterioration of regional LVEF over time in
regions remote from the site(s) of electrical stimulation,
which result in a significant reduction in global LV func-
tion. Pacing at the RVOT is associated with more synchro-
nous ventricular activation with a narrower QRS duration
and lower incidence of regional myocardial perfusion and
wall motion abnormalities, compared with RVA pacing,
and it preserves global LV systolic and diastolic function
over long-term follow-up.
Previous experimental studies. Asynchronous electrical
activation during ventricular pacing has been shown to
reduce LV function and to alter regional myocardial blood
flow and work (3,11,24). This redistribution of regional
myocardial blood flow and work is associated with abnormal
structural and histologic changes in the ventricles (6–9).
Although the mechanism remains unclear, previous exper-
imental studies have demonstrated that RVA pacing results
in greater impairment of ventricular function, as compared
with pacing at other sites (3,25,26). Prinzen et al. (3) have
demonstrated, by using magnetic resonance imaging tag-
ging, the loss of contractile function in early activated
regions with compensatory hyperfunctioning of late acti-
vated regions during ventricular pacing. However, pacing at
the RVA, but not at the LV basal region, was associated
with impairment of global LV function, suggesting that the
size of the region with reduced function appears to be too
large to be compensated during RVA pacing. Although
RVA pacing resulted in more complex and inhomogeneous
ventricular activation, with regions of rapid and slower
propagation, pacing at the LV basal region showed a steady
and consistent propagation of activation (27). This differ-
ence in myocardial activation may contribute to the larger
hypofunctional area during RVA pacing. Furthermore,
RVOT pacing that maintained synchronous ventricular
activation preserved myocardial function and prevented the
development of myofibrillar disarray (11,12).
Previous human studies. Recent clinical studies have
demonstrated that asynchronous ventricular activation dur-
ing RVA pacing is associated with impairment of LV
systolic and diastolic function, as well as alteration of
regional adrenergic innervation, myocardial blood flow, and
perfusion in patients with normal coronary arteries
Figure 5. Global left ventricular ejection fraction (LVEF) (upper panel)
and left ventricular diastolic function (lower panel) after 6 and 18 months
of right ventricular apex (RVA) (solid bars) and right ventricular outflow
tract (RVOT) (open bars) pacing. The LVEF during RVA pacing at 18
months was significantly lower than that during RVOT pacing at 18
months (p  0.05) and during RVA pacing at 6 months (p  0.05). At
both 6 and 18 months, the peak ventricular filling rate during RVA pacing
was lower than that during RVOT pacing (p  0.05).
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(1,4,5,28). Furthermore, regional perfusion defects and wall
motion abnormalities became more pronounced with an
increased duration of RVA pacing and subsequently led to
impairment of LV function (10). Therefore, the use of
alternate permanent ventricular pacing sites to prevent these
potential long-term deleterious effects have been investi-
gated.
Previous studies have demonstrated the long-term safety
and efficacy of RVOT pacing as an alternate permanent
right ventricular (RV) pacing site (29). However, investiga-
tions on the effects of RVOT pacing have yielded inconsis-
tent results. Giudici et al. (13) have revealed a significant
early hemodynamic benefit of RVOT pacing versus RVA
pacing, whereas Buckingham et al. (14) failed to show any
difference between RVOT and RVA pacing. Recently,
Victor et al. (15) demonstrated no symptomatic improve-
ment or hemodynamic benefit during RVOT pacing com-
pared with RVA pacing in patients with long-term atrial
tachyarrhythmias and complete AV block after three
months of pacing. Schwaab et al. (16) showed that a
reduction in the QRS duration by RVOT pacing is signif-
icantly correlated with homogenization of LV contraction
and with increased systolic function. However, most of
these studies involved early hemodynamic testing or only
had a limited duration of follow-up, and the long-term
effects of RVOT pacing on myocardial perfusion and
functions have not been evaluated.
Long-term effects of RV stimulation. This is the first
prospective study in humans to evaluate the long-term
effects of using a different RV stimulation site on myocardial
perfusion and function. In this study, RVOT pacing was
performed by positioning the lead in that particular site of
the interventricular septum to achieve the shortest QRS
duration on the surface ECG (16). This resulted in a
significant reduction in the QRS duration during RVOT
pacing compared with RVA pacing. After six months of
pacing, there were no significant differences in myocardial
perfusion and global LV systolic function between RVA and
RVOT pacing. However, global LV diastolic function
diminished with RVA pacing compared with RVOT pac-
ing. During both RVA and RVOT pacing, the regional
LVEF decreased at the early activated regions and increased
at the regions remote from the stimulation sites. As a result,
the global LVEF was not depressed after six months in both
groups. This may explain why previous (5) and recent
(Right ventricular Outflow tract Versus Apical pacing
[ROVA] trial) (30) clinical studies, which lasted less than
six months, failed to show a benefit of RVOT pacing.
However, after 18 months of pacing, the number of
myocardial perfusion defects and regional motion abnor-
malities were significantly higher and global LV systolic and
diastolic function was significantly lower during RVA pac-
ing compared with RVOT pacing. Furthermore, there was
also a significant interval increase in the number of myo-
cardial perfusion defects and regional motion abnormalities
and a decrease in global LVEF (14%) during RVA pacing
after one year, but not during RVOT pacing. These data
provide further evidence to support our previous findings
(10) that asynchronous electrical activation during RVA
pacing is associated with progressive worsening of myocar-
dial perfusion and function over time. Most importantly,
this study demonstrates that decreased asynchronous ven-
tricular activation with RVOT pacing is associated with a
lower incidence of regional myocardial perfusion and wall
motion abnormalities, and it preserves global LV systolic
and diastolic function over long-term follow-up.
Study limitations. First, only patients without coronary
artery disease and normal LV function were included in this
study. Therefore, whether the findings of this study are
applicable to patients with underlying heart disease or LV
dysfunction, or both, remains unclear. Second, the small
number of patients in this study is a limitation. This was due
to the strict screening criteria used in this study to exclude
other factors that might affect LV function. Third, the
clinical outcome and functional assessment, such as exercise
capacity, quality of life, and hospital admission for heart
failure, were not assessed in this study. Final, the lead
position was optimized during RVOT pacing, but not
during RVA pacing. Therefore, the result may simply
demonstrate that the minimization of QRS duration, not
the location of pacing, is important.
Conclusions. The present study demonstrates that perma-
nent RVOT pacing that preserves ventricular activation
prevents the long-term deleterious effects of “conventional”
RVA pacing on myocardial perfusion and function in
patients implanted with a permanent pacemaker. The long-
term clinical benefit of using RVOT pacing for routine
pacemaker implantation and resynchronization therapy for
congestive heart failure requires further study.
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